Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease Clinical Trial

Official title:

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV-B® to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00985426
• Other study ID #: DV2-HBV-17
• Secondary ID: 2009-015877-11
• Status: Completed
• Phase: Phase 3
• Start date: September 2009
• Est. completion date: January 2012

Study information

• Verified date: April 2021
• Source: Dynavax Technologies Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 521
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• be 18 to 75 years of age;

• progressive loss of renal function as defined by glomerular filtration rate (GFR) = 45 mL/min/1.73 m²;

• be clinically stable in the opinion of the investigator;

• be serum negative for HBsAg, anti-HBsAg, antibody to hepatitis B core antigen (HBcAg), Hepatitis C virus (HCV), and human immunodeficiency virus (HIV);

• if a woman of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase and for up to 28 days after the last injection;

• is not scheduled to undergo a kidney transplant in the next 12 months;

• be able and willing to provide informed consent.

Exclusion Criteria:

• if female, is pregnant, breastfeeding, or planning a pregnancy;

• has a history of or is considered by the investigator to be at high risk for recent exposure to HBV, HCV, or HIV; for example, current intravenous drug use, has unprotected sex with known HBV/HIV positive partner;

• has known history of autoimmune disease;

• has previously received any HBV vaccine;

• has a history of sensitivity to any component of study vaccines;

• has current illness other than renal disease or has substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study results;

• is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous or basal cell carcinoma of the skin;

• has uncontrolled diabetes or hypertension;

• is unwilling or unable to comply with all the requirements of the protocol;

• has received any blood products or immunoglobulin within 3 months prior to study entry, or likely to require infusion of blood products during the study period;

• has received the following prior to the first injection:

• 3 days: erythropoietin (exclusionary window does not apply for subjects on dialysis)

• 7 days: intravenous iron

• 21 days: any inactivated virus vaccine

• 28 days:

• any live virus vaccine

• systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication, with the exception of inhaled steroids

• granulocyte or granulocyte-macrophage colony-simulating factor (G/GM-CSF), any other investigational medicinal agent

• At any time: an injection of deoxyribonucleic acid plasmids or oligonucleotide

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Biological:
• HEPLISAV-B
Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
• Engerix-B
Intramuscular (IM) injections at Weeks 0, 4, 8, and 24

Other:
• Placebo
Placebo(saline) intramuscular (IM) injection at Week 8

Locations

Country	Name	City	State
United States	Clinical Research Associates of Tidewater	Norfolk	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Dynavax Technologies Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response	SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit [mIU]/mL) after HEPLISAV-B compared to that after Engerix-B.	Week 28
Secondary	Reactogenicity as Measured by the Percentage of Participants With Local and Systemic Post-injection Reactions Within 7 Days After Each Injection Visit	Local reactions include redness greater than or equal to 25 mm, swelling greater than or equal to 25 mm, and pain.; Systemic reactions include malaise, headache, myalgia, fatigue, and fever (temperature greater than or equal to 38ºC).; This table presents post-injection reactions at active injection visits only. Post-injection reactions after the third (placebo) injection visit in the HEPLISAV-B group are not included.	7 days after each injection visit (Weeks 0, 4, 8, and 24)
Secondary	Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response at Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52	SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit [mIU]/mL) after HEPLISAV-B compared to that after Engerix-B.	Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52
Secondary	Percentage of Participants With Anti-HBsAg Greater Than or Equal to 100 mIU/mL at Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52		Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52
Secondary	Serum Anti-HBsAg Geometric Mean Concentration (GMC) at Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52		Weeks 4, 8, 12, 18, 24, 28, 36, 44, and 52
Secondary	SPR of Participants With Type 2 Diabetes Mellitus at Week 28	SPR is the percentage of participants who have a seroprotective immune response (antibody level to anti-HBsAg greater than or equal to 10 milli-international unit [mIU]/mL) after HEPLISAV-B compared to that after Engerix-B.	Week 28

External Links

•   Related Info